MedDataX Logo

Feasibility Study of a Once Daily Antiretroviral Regimen in Vietnam (ANRS 1210 VIETAR)

NCT ID: NCT00158470

Last Updated: 2007-07-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-09-30

Study Completion Date

2007-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Access to care and treatment using antiretroviral drugs will be expanded in Vietnam in the next few years. The ANRS 1210 study is a pilot program to evaluate the feasibility of a simplified antiretroviral treatment using three antiretroviral drugs once a day. The objectives will be to assess the efficacy and the tolerance of this treatment and to better understand the difficulties linked to social and behavioural conditions of patients at different stages during the treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Despite a high number of infected subjects (estimated of 250,000 at the end of 2004) and a rapid spread of HIV infection in Vietnam, the use of anti-retroviral therapy remains limited. However, access to care and treatment will be expanded in Vietnam in the next few years with the support of national and international organisations. ANRS 1210 study is the first pilot program using highly active antiretroviral therapy (HAART) to evaluate the efficacy and the tolerance of an antiretroviral therapy delivered to adults in an external system of medical care, in Ho Chi Minh City. This feasibility study has also the objective to evaluate the cause of treatment failures and to assess social and behavioural conditions of patients at different stages during the treatment.

The present study is an open trial with direct individual benefit. The chosen treatment is a once-daily administration of 3TC, ddI and Efavirenz delivered to HIV infected adults with a CD4 count below 200/mm3. The duration of the study is eighteen months with a main evaluation at six months. One hundred patients will be selected in outpatient consultation of Binh Trieu hospital and Tropical Diseases Hospital of Ho Chi Minh City. The main criteria of evaluation will be the immunological response at 6 months, opportunistic infection events and the proportion of patients undergoing a regular monitoring at 6 months. Viral response will be also appreciated but, for technical question, will not be a main criteria of the study.

Patients are also administered a questionnaire by a trained independent interviewer about adherence to treatment, mental well-being, housing and nutrition, drug and sexual behaviour, social support and disclosure in order to study the associations between sociobehavioural dimensions, adherence and viral load at two successive follow-up visits.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

efavirenz

Intervention Type DRUG

didanosine

Intervention Type DRUG

lamivudine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Man or woman over 18 years old
* HIV infected
* Written informed consent signed
* CD4 count lower than 200/mm3
* No previous antiretroviral treatment
* Weight over 45 kilos and/or body mass index over 16
* Karnofsky Index over or equal to 70 percent

Exclusion Criteria

* Pregnant woman or woman without effective contraception
* Opportunistic infection compromising the realisation of the treatment
* Tumoral pathology
* Progressive psychiatric affection
* Previous history of peripheral neuropathy or pancreatitis
* Hemoglobin above 90 g/l
* PMN neutrophil above 1.0G/l
* Platelets above 50G/l
* Liver enzymes over 5 times the normal values
* Lipase and/or amylase over 2 times the normal values
* Prothrombin rate above 50 percent
* Plasmatic creatinine over 200 micromoles/l
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

French National Agency for Research on AIDS and Viral Hepatitis

OTHER_GOV

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jean Yves Follezou, Pr

Role: STUDY_CHAIR

CHU Pitié-Salpêtrière, Paris, France

Huu Chi Nguyen, Dr

Role: PRINCIPAL_INVESTIGATOR

Tropical Diseases Hospital - Ho Chi Minh City - Vietnam

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Binh Trieu Hospital

Ho Chi Minh City, , Vietnam

Site Status

Tropical Diseases Hospital

Ho Chi Minh City, , Vietnam

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Vietnam

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VIETAR

Identifier Type: -

Identifier Source: secondary_id

ANRS 1210 VIETAR

Identifier Type: -

Identifier Source: org_study_id